Raman imaging microscopy - A potential cost-effective tool for drug development

American Pharmaceutical Review

Volumn 8, Issue 4, 2005, Pages 44-49

  Ling, Jian ^a  

^a SOUTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1 INHIBITOR; PACLITAXEL; SULFIDE; SULFONE; SULINDAC;

CHEMICAL STRUCTURE; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; DRUG RESEARCH; IN VITRO STUDY; RAMAN SPECTROMETRY; REVIEW;

EID: 33749343202     PISSN: 10998012     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (9)

1. Ling, J., The Development of Raman Imaging Microscopy To Visualize Drug Actions in Living Cells, in Department of Biomedical Engineering. 2001, The University of Texas at Austin, p. 150.
2. Ling, J. and A.C. Bovik. Modeling and Restoration of Raman Microscopic Images, in IEEE 2000 International Conference on Image Processing (ICIP). 2000. Vancouver, Canada.
3. Ling, J. and A.C. Bovik, Smoothing Low SNR Molecular Images Via Anisotropic Median-Diffusion. IEEE Trans. Med. Imaging, 2002. 21(4).
4. Ling, J., et al. Application of Raman Imaging Microscopy to Evaluate Drug Distribution within Cancer Cells, in 91st Annual Meeting of American Association for Cancer Research. 2000. San Francisco, California.
5. Ling, J., et al., Direct Raman Imaging Techniques for Studying the Subcellular Distribution of a Drug. Applied Optics, 2002. 41(28): p. 6006-6017.
6. Alberts, B., et al., Microtubules, in Essential Cell Biology - An Introduction to the Molecular Biology of the Cell 1998, Garland Publishing: New York. p. 518-529.
7. Duggan, D.E., et al., Identification of the biologically active form of sulindac. J Pharmacol Exp Ther, 1977. 201(1): p. 8-13.
8. Piazza, G.A., et al., Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res, 1997. 57(14): p. 2909-15.
9. Thompson, W.J., et al., Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res, 2000. 60(13): p. 3338-42.